- Home
- ANGH vs OPTN Comparison
ANGH vs OPTN Comparison
Compare ANGH & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- OPTN
- Stock Information
- Founded
- ANGH 2012
- OPTN 2010
- Country
- ANGH United Arab Emirates
- OPTN United States
- Employees
- ANGH N/A
- OPTN N/A
- Industry
- ANGH Telecommunications Equipment
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- OPTN Health Care
- Exchange
- ANGH Nasdaq
- OPTN Nasdaq
- Market Cap
- ANGH 46.8M
- OPTN 55.4M
- IPO Year
- ANGH N/A
- OPTN 2017
- Fundamental
- Price
- ANGH $0.69
- OPTN $5.77
- Analyst Decision
- ANGH
- OPTN Strong Buy
- Analyst Count
- ANGH 0
- OPTN 3
- Target Price
- ANGH N/A
- OPTN $16.67
- AVG Volume (30 Days)
- ANGH 18.0K
- OPTN 18.9K
- Earning Date
- ANGH 02-28-2025
- OPTN 03-06-2025
- Dividend Yield
- ANGH N/A
- OPTN N/A
- EPS Growth
- ANGH N/A
- OPTN N/A
- EPS
- ANGH N/A
- OPTN N/A
- Revenue
- ANGH $52,274,011.00
- OPTN $75,672,000.00
- Revenue This Year
- ANGH N/A
- OPTN $13.42
- Revenue Next Year
- ANGH N/A
- OPTN $38.54
- P/E Ratio
- ANGH N/A
- OPTN N/A
- Revenue Growth
- ANGH 13.03
- OPTN 5.13
- 52 Week Low
- ANGH $0.62
- OPTN $4.82
- 52 Week High
- ANGH $2.27
- OPTN $31.50
- Technical
- Relative Strength Index (RSI)
- ANGH 44.92
- OPTN 44.78
- Support Level
- ANGH $0.63
- OPTN $5.20
- Resistance Level
- ANGH $0.72
- OPTN $6.49
- Average True Range (ATR)
- ANGH 0.05
- OPTN 0.50
- MACD
- ANGH 0.00
- OPTN 0.04
- Stochastic Oscillator
- ANGH 42.31
- OPTN 44.19
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with the catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner and is continuously licensing new content.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.